CMTM7 and breast carcinoma: Meanwhile, the transcriptional levels of CMTM7 can predict the immunotherapy response better than those of PD-1 and PD-L1, suggesting that CMTM7 is a novel biomarker that can recognize the immune-hot TME and predict the effective therapeutic response of immunotherapy in BRCA, implying that measuring the CMTM7 levels of breast cancers could guide the therapeutic schedule.